omalizumab
omalizumab: 11 clinical trials tracked.
omalizumab evidence translation
What we can confirm
11 tracked trials
What it means
What to watch
Prepared research question
What is verified about omalizumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 1 study sponsors
Clinical Trial Registry Records (11)showing 10 most recent
A Global, Multi-center, Open-label Study, Investigating a Remibrutinib- and Omalizumab-Based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-Antihistamines, to Achieve Fast and Well-Controlled Disease Within 24 Weeks
Primary endpoint: Proportion of participants achieving Urticaria Activity Score over 7 days (UAS7) ≤6 (yes/no)
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)
Primary endpoint: Rate of COPD exacerbations
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial of Exl-111 in Healthy Participants
Primary endpoint: Incidence and severity of treatment-emergent adverse events and serious adverse events for Part A and Part B
A Multicenter, Randomized, Double-Blind, Active Drug and Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in the Treatment of Patients With Moderate to Severe Persistent Allergic Asthma.
Primary endpoint: Mean number of asthma exacerbations per subject
Multi-center,Randomized,Double-blind Phase II Study to Evaluate the Efficacy and Safety of LP-003 in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
Primary endpoint: The proportion of participants achieving complete absence of wheals and itching (UAS7 = 0) at week 12
A Global, Multicenter, Randomized, Double-blind, Double-dummy, Parallel-group, Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib 25 mg b.i.d. in Comparison to Placebo With Omalizumab 300 mg Every 4 Weeks as Active Control Over 52 Weeks in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines and an Open-label 52-week Optional Extension to Assess Long-term Efficacy, Safety and Tolerability of Remibrutinib 25 mg b.i.d.
Primary endpoint: Absolute change from baseline in Weekly Urticaria Activity Score (UAS7)
Omalizumab Before Onset of Exacerbations
Primary endpoint: Nasal interferon-α (IFN-α)
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients
Primary endpoint: Change From Baseline to Week 24 in Nasal Polyp Score
Special Drug Use Observational Study of Xolair in Patients With Severe to Most Severe Seasonal Allergic Rhinitis Aged ≥ 12 Years and < 18 Years Whose Symptoms Were Inadequately Controlled Despite to Conventional Therapies
Primary endpoint: Proportions of patients with Adverse events (AEs), Serious AEs, AEs leading to discontinuation of Xolair treatment, Adverse drug reactions (ADRs), Serious ADRs, ADRs leading to discontinuation of Xolair treatment
Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes
Primary endpoint: The Success Rates of Passing a Peanut Double-Blind Placebo Controlled Food Challenge (DBPCFC)